ReviewCureus2025
Short- and Long-Term Outcomes of Neoadjuvant Chemotherapy in Operable Locally Advanced Colon Cancer: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of operable locally advanced colon cancer has traditionally centered on upfront surgical resection. The role of neoadjuvant chemotherapy (NAC) in this setting remains a subject of investigation, with potential benefits including tumor downstaging and early treatment of micrometastases. This systematic review aims to synthesize the existing evidence on the short- and long-term outcomes of NAC for patients with operable locally advanced colon cancer. A systematic literature search was conducted across PubMed/MEDLINE, Embase, Scopus, and Web of Science up to October 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies reporting on pathological response, surgical outcomes, recurrence, disease-free survival (DFS), or overall survival (OS) in patients receiving NAC for locally advanced colon cancer were included. The risk of bias was assessed using the Cochrane RoB 2 tool for randomized trials and the ROBINS-I tool for non-randomized studies. A qualitative synthesis was performed due to heterogeneity among the included studies. Twelve studies were included. Pathological complete response rates varied, reaching up to 16% with FOLFOX-based regimens in colon cancer. NAC was associated with high R0 resection rates and acceptable postoperative morbidity. A key finding was the stage-dependent survival benefit, with a significant OS improvement specifically in T4 disease but not in T3 disease. The addition of targeted therapy based on biomarker status (e.g., panitumumab in KRAS-wildtype tumors) demonstrated significant improvements in DFS and OS. Evidence from rectal cancer studies suggested that NAC could achieve outcomes comparable to neoadjuvant chemoradiotherapy. NAC is a feasible and effective strategy for operable locally advanced colon cancer, demonstrating significant pathological responses and promising survival outcomes, particularly in T4 tumors and with biomarker-directed therapy. Its efficacy is highly dependent on careful patient selection based on disease stage and molecular characteristics. Future research should focus on randomized trials in high-risk populations and the integration of personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.